<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The major goal in the treatment of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> is to control the <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> characteristic of the disease </plain></SENT>
<SENT sid="1" pm="."><plain>However, treatment with common therapies such as insulin or insulinotrophic sulphonylureas (SU), while effective in reducing <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, may impose a greater risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e>, as neither therapy is self-regulated by ambient blood <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">Hypoglycaemia</z:e> has been associated with adverse physical and psychological outcomes and may contribute to negative cardiovascular events; hence minimization of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> risk is clinically advantageous </plain></SENT>
<SENT sid="3" pm="."><plain>Stimulation of insulin secretion from pancreatic β-cells by glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> 1 receptor (GLP-1R) <z:chebi fb="4" ids="48705">agonists</z:chebi> is known to be <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent </plain></SENT>
<SENT sid="4" pm="."><plain>GLP-1R <z:chebi fb="4" ids="48705">agonists</z:chebi> potentiate <z:chebi fb="105" ids="17234">glucose</z:chebi>-stimulated insulin secretion and have little or no activity on insulin secretion in the absence of elevated blood <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations </plain></SENT>
<SENT sid="5" pm="."><plain>This '<z:chebi fb="105" ids="17234">glucose</z:chebi>-regulated' activity of GLP-1R <z:chebi fb="4" ids="48705">agonists</z:chebi> makes them useful and potentially safer therapeutics for overall <z:chebi fb="105" ids="17234">glucose</z:chebi> control compared to non-regulated therapies; <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> can be reduced with minimal <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>While the inherent mechanism of action of GLP-1R <z:chebi fb="4" ids="48705">agonists</z:chebi> mediates their <z:chebi fb="105" ids="17234">glucose</z:chebi> dependence, studies in rats suggest that SUs may uncouple this dependence </plain></SENT>
<SENT sid="7" pm="."><plain>This hypothesis is supported by clinical studies showing that the majority of events of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> in patients treated with GLP-1R <z:chebi fb="4" ids="48705">agonists</z:chebi> occur in patients treated with a concomitant SU </plain></SENT>
<SENT sid="8" pm="."><plain>This review aims to discuss the current understanding of the mechanisms by which GLP-1R signalling promotes insulin secretion from pancreatic β-cells via a <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent process </plain></SENT>
</text></document>